カテゴリ： GlobalData, アメリカ, 企業調査

Sarepta Therapeutics Inc (SRPT)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Sarepta Therapeutics Inc (SRPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9964
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：85
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Sarepta Therapeutics Inc (Sarepta) is discovers and develops unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches to treat rare neuromuscular diseases. The company develops drugs based on its proprietary, highly-differentiated and innovative platform technology, phosphorodiamidate morpholino oligomer (PMO) chemistries. Its first commercial product, Exondys 51 is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. Sarepta’s key pipeline products using PMO chemistry includes Golodirsen to skip exon 53 of the DMD gene; and Casimersen to skip exon 45 of the DMD gene. Sarepta is headquartered in Cambridge, Massachusetts, the US.

Sarepta Therapeutics Inc (SRPT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 12
Partnerships 13
InVitae Expands Partnership with Sarepta Therapeutics 13
Sarepta Therapeutics Enters into Partnership with Myonexus Therapeutics 14
Sarepta Therapeutics Enters into Research Agreement with Duke University 15
Sarepta Therapeutics Enters into Research Agreement with Genethon 16
Sarepta Therapeutics Enters into Research Agreement with Nationwide Children’s Hospital 17
Catabasis Pharma Enters into Agreement with Sarepta Therapeutics 18
Murdoch University Enters into Research Agreement with Sarepta Therapeutics 19
Sarepta Therapeutics Enters into Agreement with Flagship Biosciences 20
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 21
Licensing Agreements 22
Sarepta Therapeutics Enters into License Agreement with Lysogene 22
Sarepta Therapeutics to Enter into Option Agreement with Nationwide Children’s Hospital 23
Sarepta Therapeutics Enters into Licensing Agreement with Lacerta Therapeutics 24
Sarepta Therapeutics Enters into Licensing Agreement with BioMarin Pharma 25
Sarepta Therapeutics Enters into Licensing Agreement with Nationwide Children’s Hospital 27
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 28
Sarepta Therapeutics Enters Into Licensing Agreement With University Of Western Australia For Duchenne Muscular Dystrophy 29
Equity Offering 31
Sarepta Therapeutics to Raise USD500 Million in Public Offering of Shares 31
Sarepta Therapeutics Prices Public Offering of Shares for USD325 Million 32
Sarepta Therapeutics Prices Public Offering of Shares for USD300 Million 34
Sarepta Therapeutics to Raise USD37.5 Million in Public Offering of Shares 36
Sarepta Therapeutics Raises USD126.8 Million in Public Offering of Shares 37
Sarepta Therapeutics Completes Public Offering Of Shares For US$100.7 Million 39
Sarepta Therapeutics Raises USD125 million in Public Offering Of Shares 41
Sarepta Therapeutics Completes Public Offering Of Common Stock For US$125 Million 42
Sarepta Therapeutics Completes Private Placement Of Shares 44
Debt Offering 45
Sarepta Therapeutics Announces Exercise of Initial Purchasers’ Option for USD95 Million in Private Placement of Notes Due 2024 45
Asset Transactions 46
Sarepta Therapeutics Sells Pediatric Disease Priority Review Voucher 46
Sarepta Therapeutics Inc – Key Competitors 47
Sarepta Therapeutics Inc – Key Employees 48
Sarepta Therapeutics Inc – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Strategy And Business Planning 50
Jun 27, 2017: Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover 50
Financial Announcements 51
Oct 25, 2018: Sarepta Therapeutics announces third quarter 2018 financial results and recent corporate developments 51
Aug 08, 2018: Sarepta Therapeutics announces second quarter 2018 financial results and recent corporate developments 55
May 03, 2018: Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments 60
Mar 01, 2018: Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results and Recent Corporate Developments 63
Oct 25, 2017: Sarepta Therapeutics Announces Third Quarter 2017 Financial Results and Recent Corporate Developments 66
Jul 19, 2017: Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments 68
Apr 27, 2017: Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments 70
Feb 28, 2017: Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments 71
Corporate Communications 73
Jun 07, 2018: Sarepta Therapeutics Appoints Gilmore O’Neill, M.B., M.M.Sc. as Chief Medical Officer 73
Dec 05, 2017: Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors 74
Sep 25, 2017: Sarepta Therapeutics Appoints Guriqbal S. Basi, Ph.D. as Chief Scientific Officer 75
Apr 05, 2017: Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 76
Apr 03, 2017: Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer 77
Mar 30, 2017: Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Company’s Strategic and Scientific Advisory Board 78
Government and Public Interest 79
Apr 10, 2018: Advocacy groups urge US government to lower price of costly DMD drug 79
Product News 80
11/07/2017: Sarepta Therapeutics Announces FDA Clearance of IND for the Company’s PPMO Exon 51 Candidate, SRP-5051 80
09/06/2017: Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53 Treated with Golodirsen (SRP-4053) 81
Product Approvals 83
Nov 03, 2017: Sarepta Therapeutics and Nationwide Children’s Hospital Announce U.S. Food and Drug Administration (FDA) Clearance of the IND Application for the GALGT2 Gene Therapy Program 83
Other Significant Developments 84
Jun 25, 2018: Decode Duchenne Announces 1,000th Patient Application 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sarepta Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 12
InVitae Expands Partnership with Sarepta Therapeutics 13
Sarepta Therapeutics Enters into Partnership with Myonexus Therapeutics 14
Sarepta Therapeutics Enters into Research Agreement with Duke University 15
Sarepta Therapeutics Enters into Research Agreement with Genethon 16
Sarepta Therapeutics Enters into Research Agreement with Nationwide Children's Hospital 17
Catabasis Pharma Enters into Agreement with Sarepta Therapeutics 18
Murdoch University Enters into Research Agreement with Sarepta Therapeutics 19
Sarepta Therapeutics Enters into Agreement with Flagship Biosciences 20
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 21
Sarepta Therapeutics Enters into License Agreement with Lysogene 22
Sarepta Therapeutics to Enter into Option Agreement with Nationwide Children's Hospital 23
Sarepta Therapeutics Enters into Licensing Agreement with Lacerta Therapeutics 24
Sarepta Therapeutics Enters into Licensing Agreement with BioMarin Pharma 25
Sarepta Therapeutics Enters into Licensing Agreement with Nationwide Children's Hospital 27
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 28
Sarepta Therapeutics Enters Into Licensing Agreement With University Of Western Australia For Duchenne Muscular Dystrophy 29
Sarepta Therapeutics to Raise USD500 Million in Public Offering of Shares 31
Sarepta Therapeutics Prices Public Offering of Shares for USD325 Million 32
Sarepta Therapeutics Prices Public Offering of Shares for USD300 Million 34
Sarepta Therapeutics to Raise USD37.5 Million in Public Offering of Shares 36
Sarepta Therapeutics Raises USD126.8 Million in Public Offering of Shares 37
Sarepta Therapeutics Completes Public Offering Of Shares For US$100.7 Million 39
Sarepta Therapeutics Raises USD125 million in Public Offering Of Shares 41
Sarepta Therapeutics Completes Public Offering Of Common Stock For US$125 Million 42
Sarepta Therapeutics Completes Private Placement Of Shares 44
Sarepta Therapeutics Announces Exercise of Initial Purchasers’ Option for USD95 Million in Private Placement of Notes Due 2024 45
Sarepta Therapeutics Sells Pediatric Disease Priority Review Voucher 46
Sarepta Therapeutics Inc, Key Competitors 47
Sarepta Therapeutics Inc, Key Employees 48
Sarepta Therapeutics Inc, Subsidiaries 49

List of Figures
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Sarepta Therapeutics Inc (SRPT)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Garmin Ltd：企業の戦略・SWOT・財務情報
    Garmin Ltd - Strategy, SWOT and Corporate Finance Report Summary Garmin Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Achillion Pharmaceuticals, Inc.：企業の戦略・SWOT・財務分析
    Achillion Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Achillion Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Mersana Therapeutics Inc (MRSN)-製薬・医療分野：企業M&A・提携分析
    Summary Mersana Therapeutics Inc (Mersana) formerly Nanopharma Corp, is a biotechnology company that develops immunoconjugate therapies to improve patients’ lives. The company offers pipeline product XMT-1522, for HER-2 targeted therapies based on its Dolaflexin platform. It utilizes its Fleximer an …
  • LinkedIn Corp：企業の戦略的SWOT分析
    LinkedIn Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Euroclear Plc：企業の戦略・SWOT・財務分析
    Euroclear Plc - Strategy, SWOT and Corporate Finance Report Summary Euroclear Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Altus Power America Management LLC：電力：M&Aディール及び事業提携情報
    Summary Altus Power America Management LLC (Altus Power) is a renewable energy company that offers private investments in clean energy projects and renewable energy certificates. The company constructs, owns, operates and manages clean energy systems on commercial buildings and properties, schools a …
  • Ezz Steel Company SAE：企業の戦略・SWOT・財務情報
    Ezz Steel Company SAE - Strategy, SWOT and Corporate Finance Report Summary Ezz Steel Company SAE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Takeda Pharmaceutical Company Limited：企業のM&A・事業提携・投資動向
    Takeda Pharmaceutical Company Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Takeda Pharmaceutical Company Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • Cancom SE (COK)：企業の財務・戦略的SWOT分析
    Cancom SE (COK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Estee Lauder Companies Inc：戦略・SWOT・企業財務分析
    Estee Lauder Companies Inc - Strategy, SWOT and Corporate Finance Report Summary Estee Lauder Companies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Asplundh Tree Expert LLC：企業の戦略的SWOT分析
    Asplundh Tree Expert LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Aubert & Duval：企業の戦略・SWOT・財務情報
    Aubert & Duval - Strategy, SWOT and Corporate Finance Report Summary Aubert & Duval - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Southwestern Energy Company：企業の戦略・SWOT・財務情報
    Southwestern Energy Company - Strategy, SWOT and Corporate Finance Report Summary Southwestern Energy Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Royal KPN N.V.：企業のM&A・事業提携・投資動向
    Royal KPN N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Royal KPN N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Iowa Health System：企業の戦略的SWOT分析
    Iowa Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Tabcorp Holdings Limited (TAH)：企業の財務・戦略的SWOT分析
    Tabcorp Holdings Limited (TAH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Benesse Holdings Inc (9783)：企業の財務・戦略的SWOT分析
    Benesse Holdings Inc (9783) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • British Airways Plc：企業の戦略的SWOT分析
    British Airways Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Flexion Therapeutics Inc (FLXN)-製薬・医療分野：企業M&A・提携分析
    Summary Flexion Therapeutics Inc (Flexion) is a pharmaceutical company that develops and commercializes pain therapies. The company's products comprise FX006, FX007, and FX005. Its FX005 is a p38 mitogen-activated protein, kinase inhibitor that contains both analgesic and anti-inflammatory propertie …
  • LeMaitre Vascular Inc (LMAT)-医療機器分野：企業M&A・提携分析
    Summary LeMaitre Vascular Inc (LeMaitre Vascular) is a medical device company. It undertakes the development, manufacture, marketing and sale of devices that are used in the treatment of peripheral vascular diseases. The company offers several product lines for vascular surgery and endovascular proc …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆